Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.1%

2 terminated/withdrawn out of 22 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

19%

3 of 16 completed trials have results

Key Signals

3 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
11(50.0%)
Phase 2
8(36.4%)
Phase 3
2(9.1%)
N/A
1(4.5%)
22Total
Phase 1(11)
Phase 2(8)
Phase 3(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT05423262Phase 1Recruiting

A Study of TRK-950 in Patients With Advanced Solid Tumors

Role: lead

NCT01753570Phase 3Completed

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Role: collaborator

NCT03872947Phase 1Active Not Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Role: lead

NCT06038578Phase 2Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Role: lead

NCT02990481Phase 1Completed

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Role: lead

NCT04804943Not ApplicableRecruiting

Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)

Role: lead

NCT03727802Phase 1Completed

Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

Role: lead

NCT04282590Phase 2Withdrawn

A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)

Role: lead

NCT01660243Phase 2Terminated

Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

Role: lead

NCT03346330Phase 1Completed

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750

Role: lead

NCT02701374Phase 2Completed

Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia

Role: lead

NCT03043248Phase 1Completed

TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam

Role: lead

NCT03002233Phase 1Completed

TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus

Role: lead

NCT02480751Phase 2Completed

TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Role: lead

NCT01090037Phase 2Completed

TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Role: lead

NCT01345799Phase 2Completed

A Study of TRK-170 for the Treatment of Crohn's Disease

Role: lead

NCT01443429Phase 1Completed

A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Role: lead

NCT01513161Phase 3Completed

Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis

Role: collaborator

NCT01423435Phase 1Completed

Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males

Role: collaborator

NCT01248650Phase 1Completed

Safety Study of TRK-820 for Patient With Hemodialysis

Role: collaborator